Back to Browse Journals » Psoriasis: Targets and Therapy » Volume 2

Psoriasis: epidemiology, natural history, and differential diagnosis

Authors Basko-Plluska JL, Petronic-Rosic V

Published Date September 2012 Volume 2012:2 Pages 67—76


Received 30 May 2012, Accepted 16 July 2012, Published 11 September 2012

Juliana L Basko-Plluska, Vesna Petronic-Rosic

Department of Medicine, Section of Dermatology, University of Chicago, Chicago, IL, USA

Abstract: Psoriasis is a chronic, immune-mediated, inflammatory disease which affects primarily the skin and joints. It occurs worldwide, but its prevalence varies considerably between different regions of the world. Genetic susceptibility as well as environmental factors play an important role in determining the development and prognosis of psoriasis. Genome-wide association studies have identified many genetic loci as potential psoriasis susceptibility regions, including PSORS1 through PSORS7. Histocompatibility antigen (HLA) studies have also identified several HLA antigens, with HLA-Cw6 being the most frequently associated antigen. Epidemiological studies identified several modifiable risk factors that may predispose individuals to developing psoriasis or exacerbate pre-existing disease. These include smoking, obesity, alcohol consumption, diet, infections, medications and stressful life events. The exact mechanism by which they trigger psoriasis remains to be elucidated; however, existing data suggest that they are linked through Th1-mediated immunological pathways. The natural history of psoriasis varies depending on the clinical subtype as well as special circumstances, including pregnancy and HIV infection. In general, psoriasis is a chronic disease with intermittent remissions and exacerbations. The differential diagnosis is vast and includes many other immune-mediated, inflammatory disorders.

Keywords: psoriasis, epidemiology, natural history, differential diagnosis

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Optimal management of nail disease in patients with psoriasis

Piraccini BM, Starace M

Psoriasis: Targets and Therapy 2015, 5:25-33

Published Date: 9 January 2015

Self-management in patients with psoriasis

Pathak SN, Scott PL, West C, Feldman SR

Psoriasis: Targets and Therapy 2014, 4:19-26

Published Date: 10 July 2014

Long-term safety of biologics in the treatment of psoriasis

Panchal MR, Coope H, McKenna DJ, Alexandroff AB

Psoriasis: Targets and Therapy 2014, 4:1-9

Published Date: 12 December 2013

Role of T-cell-mediated inflammation in psoriasis: pathogenesis and targeted therapy

Flatz L, Conrad C

Psoriasis: Targets and Therapy 2013, 3:1-10

Published Date: 27 February 2013

Lipid profile in psoriasis patients

Bhat RM, Pinto HP

Psoriasis: Targets and Therapy 2012, 2:77-80

Published Date: 9 November 2012

The management of psoriasis through diet

Duarte G, Barbosa LO, Rosa ME

Psoriasis: Targets and Therapy 2012, 2:45-53

Published Date: 7 August 2012

Biologics in the treatment of psoriasis and emerging new therapies in the pipeline

Levy LL, Solomon SM, Emer JJ

Psoriasis: Targets and Therapy 2012, 2:29-43

Published Date: 18 June 2012

Optimal dose of hyperbaric bupivacaine 0.5% for unilateral spinal anesthesia during diagnostic knee arthroscopy

HM Atef, AM El-Kasaby, MA Omera, et al

Local and Regional Anesthesia 2010, 3:85-91

Published Date: 26 August 2010